Clinical Trial Update: A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of neoadjuvant modified FOLFIRINOX for resectable pancreatic adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Modified FOLFIRINOX (modified FOLFIRINOX)

Snippet

Sponsor: Yonsei University | Conditions: Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: UNKNOWN